Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.

Autor: Lowe NM; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom., Kershaw LE; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom., Bernstein JM; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Department of Otolaryngology-Head & Neck Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom., Withey SB; Medical Physics, University Hospitals Birmingham, Birmingham, United Kingdom., Mais K; Head and Neck Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Homer JJ; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.; University Department of Otolaryngology-Head & Neck Surgery, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Slevin NJ; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Head and Neck Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Bonington SC; Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Carrington BM; Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom., West CM; Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2018 Mar 28; Vol. 13 (3), pp. e0194841. Date of Electronic Publication: 2018 Mar 28 (Print Publication: 2018).
DOI: 10.1371/journal.pone.0194841
Abstrakt: Objectives: Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes.
Methods: A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response.
Results: Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23-49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21).
Conclusion: DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje